Free tool
FAERS Monitor: Axumin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208054 or its brand name (Axumin, Fluciclovine F-18). Reports on generic versions are filed under their own applications.
Reports
102
Serious
5
5% of reports
Hospitalization
2
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- positron emission tomogram abnormal22
- no adverse event18
- therapeutic response unexpected18
- scan abnormal11
- off label use8
- false negative investigation result7
- drug ineffective6
- injection site extravasation5
- false positive investigation result4
- therapeutic product effect decreased4
- diarrhoea3
- extravasation2
- malaise2
- manufacturing product shipping issue2
- product dose omission2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 14 |
| 2019 | 14 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 30 |
| 2023 | 8 |
| 2024 | 4 |
| 2025 | 26 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,057 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| positron emission tomogram abnormalSignal | 22 | 6707.6 | 4597.8 | 136,464 |
| scan abnormalSignal | 11 | 6342.3 | 3594.9 | 61,653 |
| false negative investigation resultSignal | 7 | 2076.0 | 1011.7 | 12,393 |
| false positive investigation resultSignal | 4 | 820.7 | 313.4 | 2,497 |
| manufacturing product shipping issue | 2 | 763.1 | 193.0 | 852 |
| extravasation | 2 | 100.4 | 25.4 | 110 |
| injection site extravasationSignal | 5 | 83.6 | 35.6 | 330 |
| therapeutic response unexpectedSignal | 18 | 82.8 | 54.4 | 1,376 |
| no adverse eventSignal | 18 | 20.5 | 13.5 | 317 |
| therapeutic product effect decreasedSignal | 4 | 18.4 | 7.0 | 50 |
| product dose omission | 2 | 6.3 | 1.6 | 4 |
| off label use | 8 | 1.9 | 1.0 | 3 |
| diarrhoea | 3 | 1.0 | 0.3 | 0 |
| malaise | 2 | 0.9 | 0.2 | 0 |
| drug ineffective | 6 | 0.9 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.